Management of Hypertension in Primary Care Safety-Net Clinics in the United States: A Comparison of Community Health Centers and Private Physicians' Offices

Health Services Research

Volumn 52, Issue 2, 2017, Pages 807-825

  Fontil, Valy ^a,b   Bibbins Domingo, Kirsten ^a,b,c   Nguyen, Oanh Kieu ^d   Guzman, David ^a   Goldman, Lauren Elizabeth ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

clinical inertia; community health centers; fixed dose combination; Hypertension; single pill combination; treatment intensification

Indexed keywords

ALDOSTERONE ANTAGONIST; ANTIHYPERTENSIVE AGENT; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DISEASE CONTROL; DRUG USE; FEMALE; HEALTH CENTER; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAID; PATIENT SAFETY; PRIMARY MEDICAL CARE; PRIVATE HEALTH INSURANCE; PROTOCOL COMPLIANCE; RESISTANT HYPERTENSION; UNITED STATES; VERY ELDERLY; ADOLESCENT; HEALTH CARE SURVEY; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PRIVATE PRACTICE; SAFETY NET HOSPITAL; STANDARDS; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; COMMUNITY HEALTH CENTERS; FEMALE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; HYPERTENSION; MALE; MEDICAID; MIDDLE AGED; PRIVATE PRACTICE; SAFETY-NET PROVIDERS; UNITED STATES; YOUNG ADULT;

EID: 84978371292     PISSN: 00179124     EISSN: 14756773     Source Type: Journal    
DOI: 10.1111/1475-6773.12516     Document Type: Article

References (36)

1. Basile, J., and J. Neutel. 2010. “Overcoming Clinical Inertia to Achieve Blood Pressure Goals: The Role of Fixed-Dose Combination Therapy.” Therapeutic Advances in Cardiovascular Disease 4 (2): 119–27.
2. Byrd, J. B., C. Zeng, H. M. Tavel, D. J. Magid, P. J. O'Connor, K. L. Margolis, J. V. Selby, and P. M. Ho. 2011. “Combination Therapy as Initial Treatment for Newly Diagnosed Hypertension.” American Heart Journal 162 (2): 340–6.
3. Calhoun, D. A., D. Jones, S. Textor, D. C. Goff, T. P. Murphy, R. D. Toto, A. White, W. C. Cushman, W. White, D. Sica, K. Ferdinand, T. D. Giles, B. Falkner, and R. M. Carey; American Heart Association Professional Education Committee. 2008. “Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.” Circulation 117 (25): e510–26.
4. Chatzizisis, Y. S., M. Jonas, R. Beigel, A. U. Coskun, A. B. Baker, B. V. Stone, C. Maynard, R. G. Gerrity, W. Daley, E. R. Edelman, C. L. Feldman, and P. H. Stone. 2009. “Attenuation of Inflammation and Expansive Remodeling by Valsartan Alone or in Combination with Simvastatin in High-Risk Coronary Atherosclerotic Plaques.” Atherosclerosis 203 (2): 387–94.
5. Chobanian, A. V., G. L. Bakris, H. R. Black, W. C. Cushman, L. A. Green, J. L. Izzo Jr, D. W. Jones, B. J. Materson, S. Oparil, J. T. Wright Jr, and E. J. Roccella; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. 2003. “The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report.” Journal of the American Medical Association 289 (19): 2560–72.
6. Clark 3rd, D., M. I. Ahmed, and D. A. Calhoun. 2012. “Resistant Hypertension and Aldosterone: An Update.” Canadian Journal of Cardiology 28 (3): 318–25.
7. “Convenient Prescription Refills from 4” [accessed on 12/6/2015]. Available at http://www.walmart.com/cp/1078664?adid=22222222320218484672&wmlspartner=wmtlabs&wl0=b&wl1=g&wl2=c&wl3=25615513554&wl4=&veh=sem
8. Croskerry, P. 2002. “Achieving Quality in Clinical Decision Making: Cognitive Strategies and Detection of Bias.” Academic Emergency Medicine 9 (11): 1184–204.
9. Dickson, M., and C. A. Plauschinat. 2008. “Racial Differences in Medication Compliance and Healthcare Utilization among Hypertensive Medicaid Recipients: Fixed-Dose vs Free-Combination Treatment.” Ethnicity and Disease 18 (2): 204–9.
10. Epstein, M., and D. A. Calhoun. 2011. “Aldosterone Blockers (Mineralocorticoid Receptor Antagonism) and Potassium-Sparing Diuretics.” The Journal of Clinical Hypertension (Greenwich) 13 (9): 644–8.
11. Farley, T. A., M. A. Dalal, F. Mostashari, and T. R. Frieden. 2010. “Deaths Preventable in the U.S. by Improvements in Use of Clinical Preventive Services.” American Journal of Preventive Medicine 38 (6): 600–9.
12. Fontil, V., M. J. Pletcher, R. Khanna, D. Guzman, R. Victor, and K. Bibbins-Domingo. 2014. “Physician Underutilization of Effective Medications for Resistant Hypertension at Office Visits in the United States: NAMCS 2006-2010.” Journal of General Internal Medicine 29 (3): 468–76.
13. Fontil, V., K. Bibbins-Domingo, D. S. Kazi, S. Sidney, P. G. Coxson, R. Khanna, R. G. Victor, and M. J. Pletcher. 2015. “Simulating Strategies for Improving Control of Hypertension among Patients with Usual Source of Care in the United States: The Blood Pressure Control Model.” Journal of General Internal Medicine 30 (8): 1147–55.
14. Goldman, L. E., P. W. Chu, H. Tran, M. J. Romano, and R. S. Stafford. 2012. “Federally Qualified Health Centers and Private Practice Performance on Ambulatory Care Measures.” American Journal of Preventive Medicine 43 (2): 142–9.
15. Gonzaga, C. C., and D. A. Calhoun. 2008. “2008 American Heart Association Statement on Diagnosis, Evaluation, and Treatment of Resistant Hypertension: What Should We Remember in Everyday Practice?” Polskie Archiwum Medycyny Wewnetrznej 118 (7–8): 396–7.
16. Harle, C. A., J. S. Harman, and S. Yang. 2013. “Physician and Patient Characteristics Associated with Clinical Inertia in Blood Pressure Control.” The Journal of Clinical Hypertension (Greenwich) 15 (11): 820–4.
17. Heisler, M., M. M. Hogan, T. P. Hofer, J. A. Schmittdiel, M. Pladevall, and E. A. Kerr. 2008. “When More Is Not Better: Treatment Intensification among Hypertensive Patients with Poor Medication Adherence.” Circulation 117 (22): 2884–92.
18. Hong, C. S., S. J. Atlas, Y. Chang, S. V. Subramanian, J. M. Ashburner, M. J. Barry, and R. W. Grant. 2010. “Relationship between Patient Panel Characteristics and Primary Care Physician Clinical Performance Rankings.” Journal of the American Medical Association 304 (10): 1107–13.
19. James, P. A., S. Oparil, B. L. Carter, W. C. Cushman, C. Dennison-Himmelfarb, J. Handler, D. T. Lackland, M. L. LeFevre, T. D. MacKenzie, O. Ogedegbe, S. C. Smith Jr, L. P. Svetkey, S. J. Taler, R. R. Townsend, J. T. Wright Jr, A. S. Narva, and E. Ortiz. 2014. “2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8).” Journal of the American Medical Association 311 (5): 507–20.
20. Jaques, H.; National Institute for Health and Clinical Excellence (NICE). 2013. “NICE Guideline on Hypertension.” European Heart Journal 34 (6): 406–8.
21. Katerndahl, D. A., R. Wood, and C. R. Jaen. 2010. “A Method for Estimating Relative Complexity of Ambulatory Care.” The Annals of Family Medicine 8 (4): 341–7.
22. Kershaw, K. N., A. V. Diez Roux, S. A. Burgard, L. D. Lisabeth, M. S. Mujahid, and A. J. Schulz. 2011. “Metropolitan-Level Racial Residential Segregation and Black-White Disparities in Hypertension.” American Journal of Epidemiology 174 (5): 537–45.
23. Khanna, R. R., R. G. Victor, K. Bibbins-Domingo, M. F. Shapiro, and M. J. Pletcher. 2012. “Missed Opportunities for Treatment of Uncontrolled Hypertension at Physician Office Visits in the United States, 2005 through 2009.” Archives of Internal Medicine 172 (17): 1344–5.
24. Ku, L., E. Jones, P. Shin, F. R. Byrne, and S. K. Long. 2011. “Safety-net Providers after Health Care Reform: Lessons from Massachusetts.” Archives of Internal Medicine 171 (15): 1379–84.
25. Kuschnir, E., E. Acuna, D. Sevilla, J. Vasquez, M. Bendersky, J. Resk, and R. Glazer. 1996. “Treatment of Patients with Essential Hypertension: Amlodipine 5 mg/Benazepril 20 mg Compared with Amlodipine 5 mg, Benazepril 20 mg, and Placebo.” Clinical Therapeutics 18 (6): 1213–24.
26. Mancia, G., R. Fagard, K. Narkiewicz, J. Redon, A. Zanchetti, M. Böhm, T. Christiaens, R. Cifkova, G. De Backer, A. Dominiczak, M. Galderisi, D. E. Grobbee, T. Jaarsma, P. Kirchhof, S. E. Kjeldsen, S. Laurent, A. J. Manolis, P. M. Nilsson, L. M. Ruilope, R. E. Schmieder, P. A. Sirnes, P. Sleight, M. Viigimaa, B. Waeber, F. Zannad, J. Redon, A. Dominiczak, K. Narkiewicz, P. M. Nilsson, M. Burnier, M. Viigimaa, E. Ambrosioni, M. Caufield, A. Coca, M. H. Olsen, R. E. Schmieder, C. Tsioufis, P. van de Borne, J. L. Zamorano, S. Achenbach, H. Baumgartner, J. J. Bax, H. Bueno, V. Dean, C. Deaton, C. Erol, R. Fagard, R. Ferrari, D. Hasdai, A. W. Hoes, P. Kirchhof, J. Knuuti, P. Kolh, P. Lancellotti, A. Linhart, P. Nihoyannopoulos, M. F. Piepoli, P. Ponikowski, P. A. Sirnes, J. L. Tamargo, M. Tendera, A. Torbicki, W. Wijns, S. Windecker, D. L. Clement, A. Coca, T. C. Gillebert, M. Tendera, E. A. Rosei, E. Ambrosioni, S. D. Anker, J. Bauersachs, J. B. Hitij, M. Caulfield, M. De Buyzere, S. De Geest, G. A. Derumeaux, S. Erdine, C. Farsang, C. Funck-Brentano, V. Gerc, G. Germano, S. Gielen, H. Haller, A. W. Hoes, J. Jordan, T. Kahan, M. Komajda, D. Lovic, H. Mahrholdt, M. H. Olsen, J. Ostergren, G. Parati, J. Perk, J. Polonia, B. A. Popescu, Z. Reiner, L. Rydén, Y. Sirenko, A. Stanton, H. Struijker-Boudier, C. Tsioufis, P. van de Borne, C. Vlachopoulos, M. Volpe, and D. A. Wood. 2013. “2013 ESH/ESC Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).” European Heart Journal 34 (28): 2159–219.
27. Nwankwo, T., S. S. Yoon, V. Burt, and Q. Gu. 2013. “Hypertension among Adults in the United States: National Health and Nutrition Examination Survey, 2011-2012.” NCHS Data Brief 2013: 1–8.
28. Ouzan, J., C. Perault, A. M. Lincoff, E. Carre, and M. Mertes. 2002. “The Role of Spironolactone in the Treatment of Patients with Refractory Hypertension.” American Journal of Hypertension 15 (4 Pt 1): 333–9.
29. Pimenta, E., and D. A. Calhoun. 2012. “Resistant Hypertension: Incidence, Prevalence, and Prognosis.” Circulation 125 (13): 1594–6.
30. Rabbani, A., and G. C. Alexander. 2008. “Out-of-Pocket and Total Costs of Fixed-Dose Combination Antihypertensives and Their Components.” American Journal of Hypertension 21 (5): 509–13.
31. Schoenthaler, A., E. Montague, L. Baier Manwell, R. Brown, M. D. Schwartz, and M. Linzer. 2014. “Patient-Physician Racial/Ethnic Concordance and Blood Pressure Control: The Role of Trust and Medication Adherence.” Ethnicity & Health 19 (5): 565–78.
32. Shaya, F. T., D. Du, F. Frech-Tamas, H. Lau, H. Fatodu, and H. Garber. 2008. “Predictors of Fixed-Dose Combination Antihypertensive Drug Therapy in a Medicaid Population.” Journal of the American Society of Hypertension 2 (6): 469–75.
33. Shi, L., L. A. Lebrun, J. Tsai, and J. Zhu. 2010. “Characteristics of Ambulatory Care Patients and Services: A Comparison of Community Health Centers and Physicians' Offices.” Journal of Health Care for the Poor and Underserved 21 (4): 1169–83.
34. Vaclavik, J., R. Sedlak, M. Plachy, K. Navratil, J. Plasek, J. Jarkovsky, T. Vaclavik, R. Husar, E. Kocianova, and M. Taborsky. 2011. “Addition of Spironolactone in Patients with Resistant Arterial Hypertension (ASPIRANT): A Randomized, Double-Blind, Placebo-Controlled Trial.” Hypertension 57 (6): 1069–75.
35. Wald, D. S., M. Law, J. K. Morris, J. P. Bestwick, and N. J. Wald. 2009. “Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-Analysis on 11,000 Participants from 42 Trials.” American Journal of Medicine 122 (3): 290–300.
36. Williams, B., T. M. MacDonald, S. Morant, D. J. Webb, P. Sever, G. McInnes, I. Ford, J. K. Cruickshank, M. J. Caulfield, J. Salsbury, I. Mackenzie, S. Padmanabhan, and M. J. Brown; British Hypertension Society's PATHWAY Studies Group. 2015. “Spironolactone Versus Placebo, Bisoprolol, and Doxazosin to Determine the Optimal Treatment for Drug-Resistant Hypertension (PATHWAY-2): A Randomised, Double-Blind, Crossover Trial.” Lancet 386 (10008): 2059–68. doi: 10.1016/S0140-6736(15)00257-3.